|
Volumn 19, Issue 1, 2013, Pages 29-30
|
In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: Commentary
|
Author keywords
[No Author keywords available]
|
Indexed keywords
FINGOLIMOD;
FUMARIC ACID DIMETHYL ESTER;
GLATIRAMER;
INTERFERON;
INTERFERON BETA SERINE;
LAQUINIMOD;
TERIFLUNOMIDE;
ANTIINFLAMMATORY ACTIVITY;
ARTICLE;
DISEASE CONTROL;
DRUG COST;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
FLUSHING;
GASTROINTESTINAL SYMPTOM;
HUMAN;
MULTIPLE SCLEROSIS;
SIDE EFFECT;
TERATOGENICITY;
|
EID: 84872329963
PISSN: 13524585
EISSN: 14770970
Source Type: Journal
DOI: 10.1177/1352458512470507 Document Type: Article |
Times cited : (6)
|
References (6)
|